A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

Inclusion Criteria:

- T1D for at least 6 months at the screening visit.

- Have been treated with only one of the following rapid-acting insulin analogs as part
of an multiple daily injection regimen for at least the last 90 days prior to the
screening visit:

- insulin lispro U-100, or

- insulin aspart

- insulin glulisine or

- fast acting insulin aspart

- Have been treated with only one of the following basal insulins for at least the last
90 days prior to the screening visit:

- insulin glargine U-100 (once a day [QD] or twice a day [BID]), or

- insulin detemir U-100 (QD or BID), or

- insulin degludec U-100 (QD)

- Have a HbA1c value ≥6.5% and ≤9.5% at the screening visit.

Exclusion Criteria:

- Have current hypoglycemic unawareness or have had more than 1 episode of severe
hypoglycemia within 6 months prior to the screening visit.

- Have had more than 1 emergency room visit or hospitalization due to poor glucose
control within 6 months prior to the screening visit.

- Have been on a treatment regimen that includes regular human insulin, neutral
protamine Hagedorn (NPH), Afrezza® (insulin human) inhalation powder, any premixed
insulins or use of diluted insulins within 90 days prior to the screening visit.